With the development of targeted therapeutics such as Tyrosine Kinase Receptor inhibitors (TKI) Imatinib, the treatment of rare diseases such as gastrointestinal stromal tumors (GIST) is certainly to the extent that there has been no cure for medicine, the drug has become ″drug to disease,″ but the problems of primary and secondary resistance to gastrointestinal stromal tumors and when it is possible to stop the drug are the key to limite the further improvement to fit sefficacy. Heat shock protein90 (HSP90) inhibitor scan by pass tyrosine kinase receptors and directly act on the protective umbrella HSP90 of the down stream signaling molecules, indirectly degrading down stream signaling molecules and disrupting abnormally activated signaling pathways. This inhibits the growth of gastrointestinal stromal tumors. In recent years, HSP90 inhibitors have been used in clinical trials as a third-line treatment for gastrointestinal stromal tumors. With the continuous development and mutual promotion of pharmacology, molecular biology, bioinformatics and other disciplines, application of next-generation sequencing technology such as BEAMing technology, the application prospects of HSP90 inhibitors will gradually become brighter.